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 Background African American (AA) women have a disproportionately high incidence of estrogen receptor–negative (ER-) 
breast cancer, a subtype with a largely unexplained etiology. Because childbearing patterns also differ by race/
ethnicity, with higher parity and a lower prevalence of lactation in AA women, we investigated the relation of par-
ity and lactation to risk of specific breast cancer subtypes.
 Methods Questionnaire data from two cohort and two case-control studies of breast cancer in AA women were combined 
and harmonized. Case patients were classified as ER+ (n = 2446), ER- (n = 1252), or triple negative (ER-, PR-, HER2-; 
n = 567) based on pathology data; there were 14 180 control patients. Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were estimated in polytomous logistic regression analysis with adjustment for study, age, reproductive 
and other risk factors.
 Results ORs for parity relative to nulliparity was 0.92 (95% CI = 0.81 to 1.03) for ER+, 1.33 (95% CI = 1.11 to 1.59) for ER-, 
and 1.37 (95% CI = 1.06 to 1.70) for triple-negative breast cancer. Lactation was associated with a reduced risk of 
ER- (OR = 0.81, 95% CI = 0.69 to 0.95) but not ER+ cancer. ER- cancer risk increased with each additional birth in 
women who had not breastfed, with an OR of 1.68 (95% CI = 1.15 to 2.44) for 4 or more births relative to one birth 
with lactation.
 Conclusions The findings suggest that parous women who have not breastfed are at increased risk of ER- and triple-negative 
breast cancer. Promotion of lactation may be an effective tool for reducing occurrence of the subtypes that con-
tribute disproportionately to breast cancer mortality.
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Breast tumors characterized by a lack of estrogen receptors (ERs) 
are associated with an aggressive pathology and poor prognosis 
(1). They occur more frequently in African American (AA) than 
other US women at every age (1,2). The causal etiology of ER- 
breast cancer is largely unexplained. It has long been thought 
that parous women have a reduced risk of breast cancer (3), 
but recent research indicates that this applies primarily to ER+ 
breast cancer (4,5). In fact, preliminary evidence suggests that 
parous women may actually have an increased risk of ER- breast 
cancer, and that the increase may be ameliorated by breastfeed-
ing (6–12). If so, the higher parity (13,14) and lower prevalence 
of lactation (15,16) in AA women relative to white women could 
be a contributor to the racial disparity in ER- cancer. Lactation 
uptake has improved in the United States in the past 30 years, 
but increases in AA women have been the smallest; in the most 
recent prevalence report from the National Immunization Survey 
(2008 data), the percentage of infants who had ever breastfed had 
increased to 58.9% among black infants as compared with 75.2% 
among white infants (17). In a collaborative project that pools 
data and samples from four large ongoing studies, we investi-
gated the relation of parity and lactation to specific subtypes of 
breast cancer in AA women.
Methods
Study Population
The present analysis is based on data from the African American 
Breast Cancer Epidemiology and Risk (AMBER) Consortium, a 
collaboration of four epidemiologic studies with large numbers of 
AA participants. The individual studies—Black Women’s Health 
Study (BWHS) (18), Multiethnic Cohort Study (MEC) (19), 
Carolina Breast Cancer Study (CBCS) (20), and Women’s Circle 
of Health Study (WCHS) (21,22)—and the AMBER consortium 
(23) have been described in detail previously. Institutional Review 
Board approval was granted for each individual study and for the 
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AMBER consortium, and informed consent was provided by all 
study participants.
Briefly, the BWHS is a prospective cohort study of 59 000 African 
American women who were enrolled by mail questionnaire in 1995 
and have been followed by biennial questionnaire since then. Median 
age at baseline was 38 years, range 21 to 69 years. Breast cancer 
cases are identified through self-report and are confirmed by medi-
cal records or through linkage with state cancer registries and the 
National Death Index. The MEC is also a prospective cohort study, 
begun in 1993 and including participants aged 45 to 69 years from 
Hawaii and Southern California, with AAs primarily from California. 
Data collection is by mail questionnaire, with follow-up question-
naires mailed at five-year intervals, and linkage with the California 
and Hawaii state cancer registries and the National Death Index. For 
both BWHS and MEC, AMBER includes all incident breast cancer 
case patients and four control patients per case selected from the 
cohort, frequency matched to cases on five-year age category and 
questionnaire completed most recently (prior to case diagnosis).
The CBCS, a population-based case-control study, was con-
ducted in North Carolina from 1993 through 2001 and included 
women aged 20 to 74 years. Cases were identified through the 
North Carolina Central Cancer Registry and control patients 
from Division of Motor Vehicle lists (age <65 years) and Health 
Care Financing Administration lists (age ≥ 65 years). Data were 
collected by in-person interview. The WCHS is an ongoing case-
control study that was initiated in 2002 in New York City hospitals 
and later expanded to several counties in New Jersey. Breast can-
cer case patients, aged 20 to 75 years, are identified through the 
New Jersey Cancer Registry and control patients through random 
digit dialing of residential telephone and cell phone numbers and 
through churches and community organizations, with data collec-
tion by in-person interview.
Eligible case patients for the present analysis were 5087 
women with a first diagnosis of invasive breast cancer or ductal 
carcinoma in situ. Pathology data from hospital records or can-
cer registry records were used to classify cancers by subtype based 
on ER, progesterone receptor (PR), and human epidermal recep-
tor 2 (HER2). Case patients were classified as ER+ or PR+ if 
expression of the marker was greater than zero. Case patients 
were classified as triple negative (ER-, PR-, HER2-) if HER2 
results were reported as zero or 1+, or were 2+ by immunohis-
tochemistry but negative by fluorescence in situ hybridization. 
Because HER2 testing was uncommon before 2005, HER2 data 
were missing for over 50% of case patients. Case patients with 
missing data on ER status (n = 1371) were excluded, as were case 
patients with missing data on parity (n = 18), leaving a total of 3698 
case patients for analysis. Among those case patients, 63% had 
HER2 data.
Statistical Analysis
Each study had collected data on age at first birth and number of 
births, and all except MEC had data on year of last birth and breast-
feeding (ever or never) for most participants. Polytomous logistic 
regression models were used to calculate odds ratios (ORs) and 
95% confidence intervals (CIs) for the relation of parity and lacta-
tion to risk of ER+ and ER- breast cancer. Separate analyses were 
carried out for triple-negative breast cancer using conventional 
logistic regression. Reduced models controlled for age in five-year 
Table 1. Characteristics of breast cancer case patients and control patients by study
Characteristics BWHS* N (%) CBCS* N (%) MEC* N (%) WCHS* N (%) Total N (%)
Breast cancer case patients
 Total 1290 804 826 778 3698
 ER+ 846 (65.6) 436 (54.2) 611 (74.0) 553 (71.1) 2446 (66.1)
 ER- 444 (34.4) 368 (45.8) 215 (26.0) 225 (28.9) 1252 (33.9)
 ER-, PR-, HER2- 153 210 74 130 567
Age at diagnosis, y
 <40 97 (7.5)  129 (16.0)  0 (0.0) 97 (12.5)  323 (8.7)
 40–49 380 (29.5)  262 (32.6) 10 (1.2) 209 (26.9)  861 (23.3)
 50–59 447 (34.7)  190 (23.9) 124 (15.0) 278 (35.7)  1039 (28.1)
 ≥60 366 (28.4)  223 (27.7) 692 (83.8) 194 (24.9)  1475 (39.9)
Childbearing factors among control patients
Number of births
 0 1907 (23.0)  86 (10.9) 560 (13.6) 156 (16.1) 2709 (19.1)
 1 1888 (22.8) 136 (17.3) 701 (17.0) 223 (22.9) 2948 (20.8)
 2 2249 (27.1) 196 (24.9) 825 (20.0) 271 (27.9) 3541 (25.0)
 3 1199 (14.5) 139 (17.6) 636 (15.4) 166 (17.1) 2140 (15.1)
 ≥4 1044 (12.6) 231 (29.3) 1411 (34.1) 156 (16.1) 2842 (20.0)
Lactation, among parous women
 Never 3576 (57.1) 424 (60.4)  —† 422 (51.7) 4422 (56.8)
 Ever 2692 (42.9) 278 (39.6)  —† 394 (48.3) 3364 (43.2)
Age at first birth, y
 <20 1989 (31.5) 348 (49.8) 1894 (55.4) 314 (38.6) 4545 (40.4)
 20–24 2203 (34.9) 216 (30.9) 997 (29.2) 246 (30.2) 3662 (32.6)
 25–29 1246 (19.7)  82 (11.7) 341 (10.0) 120 (14.7) 1789 (15.9)
 ≥30  871 (13.8)  53 (7.6) 184 (5.4) 134 (16.5) 1242 (11.1)
* BWHS = Black Women’s Health Study; CBCS = Carolina Breast Cancer Study; MEC = Multiethnic Cohort; WCHS = Women’s Circle of Health Study.
† Lactation data not available for most MEC participants.
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Figure 1. Odds ratios for number of births in relation to ER- and ER+ breast cancer, according to lactation history. Reference is women who had 
only one birth and had breastfed.
categories, study, geographic region, and period (1993–1998, 
1999–2005, and 2006–2013). Multivariable models controlled for 
those factors plus family history of breast cancer, age at menarche, 
oral contraceptive use, body mass index, years of education, alcohol 
consumption, and cigarette smoking. Analyses restricted to parous 
women additionally controlled for age at first birth, years since 
last birth, and number of births. A meta-analysis of study-specific 
results was performed under a random-effects model. All statistical 
tests were two-sided, with P less than .05 used as the cutpoint for 
statistical significance. To test for trend across number of births, an 
ordinal variable was treated as a continuous variable in the regres-
sion models. Interaction on the multiplicative scale was tested by 
the likelihood ratio test, comparing models with and without mul-
tiplicative interaction terms. Analyses were performed using SAS 
9.2 statistical software (SAS Institute Inc., Cary, NC).
To assess whether pregnancy-associated breast cancers (24) 
(PABC)—breast cancer within 10 years of a birth—differ by subtype, 
we compared the relative proportions of ER+ and ER- tumors among 
PABC and non-PABC within strata of age at diagnosis: younger than 
age 40 years, 40–44, and 45 years and older. Stratifying by age at 
diagnosis is critical because the relative proportion of ER- tumors 
decreases with age, and time since last birth is also related to age.
results
Table 1 gives characteristics of the study participants. There were 
14 180 control patients, 2446 ER+ breast cancer case patients, and 
1252 ER- breast cancer case patients; of the ER- case patients, 567 
could be classified as triple negative. The CBCS had the highest 
proportion of ER- case patients and the MEC the lowest, largely 
reflecting the age distributions of the various studies. Distributions 
of parity and age at first birth differed by study, with higher parity 
and earlier age at first birth in the CBCS and MEC, studies that 
disproportionately included earlier birth cohorts and women of low 
socioeconomic status. Overall, 43% of parous control patients had 
breastfed at least one baby, with similar proportions across studies.
The multivariable OR for ever-parous vs nulliparous in rela-
tion to ER+ breast cancer was 0.92 (95% CI = 0.81 to 1.03), and 
there was not a statistically significant trend with increasing 
number of births (Table 2). Lactation was not associated with a 
reduced risk. By contrast, parity was associated with an increased 
risk of ER- breast cancer (multivariable OR = 1.33, 95% CI = 1.11 
to 1.59), and risk increased with increasing number of births 
(Ptrend  =  .04). Among parous women, ever lactation was associ-
ated with a reduced risk of ER- breast cancer (OR = 0.81, 95% 
CI = 0.69 to 0.95). For triple-negative breast cancer, ORs were 
1.37 (95% CI = 1.06 to 1.79) for ever vs never parous and 0.81 
(0.65 to 1.02) for ever vs never lactation. A meta-analysis of study-
specific results yielded ORs very similar to results from pooling 
of individual data: ORs for parous vs nulliparous were 0.86 (95% 
CI = 0.71 to 1.06) for ER+ cancer and 1.27 (95% CI = 1.06 to 
1.53) for ER- cancer, and ORs for ever vs never lactation were 
1.01 (95% CI = 0.79 to 1.31) and 0.79 (0.64 to 0.98) for ER+ and 
ER- cancer, respectively.
The joint effects of parity and lactation were assessed in analyses 
restricted to parous women, with a reference category of women 
who had only one birth and had breastfed (Table 2 and Figure 1). In 
the fully adjusted model, ORs for ER+ cancer were below 1.0 but 
not statistically significant for the highest parity category, regard-
less of lactation status. Risk of ER- breast cancer increased mark-
edly by increasing parity among women who had never breastfed, 
with ORs ranging from 1.22 (95% CI = 0.88 to 1.69) for one birth 
to 1.68 (95% CI = 1.15 to 2.44) for four or more births. The ORs 
for similar comparisons among women who had breastfed were 
considerably lower, below 1.2 in all categories except four or more 
births (1.33, 95% CI = 0.91 to 1.95). For triple-negative breast can-
cer, there was no evidence of an association among women who had 
breastfed, whereas the OR for four or more births among women 
who had not breastfed was 1.51 (95% CI = 0.90 to 2.52).
As shown in Table 3, results were similar across age strata (all 
Pinteraction values > .05). For ER+ breast cancer, ORs for parity were 
below or at 1.0 in each age group, and there was no evidence of an 
association with lactation in any age group. For ER- breast cancer, 
ORs for parity were above 1.0 in every age group, with the highest 
OR observed for patients younger than age 40 years; ORs for lacta-
tion relative to never lactation were below 1.0 in every age group.
Figure 2 displays ORs for parity relative to nulliparity according 
to years since completion of childbearing. For ER+ breast cancer, 
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all ORs were below 1.0, and the OR for 25 or more years since last 
birth was 0.82 (95% CI = 0.69 to 0.97). In contrast, for ER- cancer, 
all ORs were greater than 1.0, and the OR for 25 or more years 
since last birth was 1.27 (95% CI = 0.99 to 1.64).
PABC and non-PABC were similar with respect to the propor-
tion of ER- tumors in each age group: 52% among PABC and 49% 
among non-PABC before age 40 years; 43% and 44% at ages 40 to 
44 years; and 34% and 35% at ages 45 years and older.
In analyses stratified on age at first birth (data not shown), parity 
was associated with reduced risk of ER+ cancer for women with first 
birth before age 25 years (OR = 0.83, 95% CI = 0.73 to 0.94) but 
not for women with a later first birth. For ER- cancer, parity was 
associated with increased risk both among women younger than age 
25 years at first birth (OR = 1.33, 95% CI = 1.10 to 1.60) and aged 
25 or older years at first birth (OR = 1.33, 95% CI = 1.07 to 1.65).
Results were similar when analyses were restricted to invasive 
breast cancers (87% of total). Results for tumors classified as ER+/PR+ 
were similar to results for all ER+ tumors and results for ER-/PR- 
tumors were similar to results for all ER- tumors (data not shown).
Discussion
In this collaborative study of breast cancer in AA women, parous 
women were estimated to have a 33% higher risk of ER- breast 
cancer and a 37% higher risk of triple-negative breast cancer, rela-
tive to nulliparous women. Breastfeeding modified the association 
with parity: At each level of parity, women who had breastfed had a 
lower risk of ER- and triple-negative breast cancer than did women 
who had never breastfed. The observed associations were not con-
fined to early-onset breast cancer or to breast cancer that occurred 
relatively soon after a pregnancy.
Most previous studies have been underpowered to assess risk 
factors for ER- or triple-negative breast cancer. About half pro-
vide evidence for an association of parity with increased risk of ER- 
breast cancer (6–12,25–27), while the others indicate no association 
(28–38). Evidence regarding breastfeeding is more consistent, with 
most but not all studies indicating an inverse association of lacta-
tion with risk of ER- breast cancer (6,8,9,11,27–31,34,36,37,39). 
A notable exception is the recent case-case analysis of breast cancer 
in women of Mexican descent, which compared 159 triple-negative 
with 571 luminal A breast cancers (26). While parity was higher 
among triple-negative case patients, the prevalence of lactation 
was higher among triple-negative case patients than luminal A case 
patients, even taking into account the number of births.
With 1252 ER- breast cancer case patients, including 567 classi-
fied as triple negative, the present study provides strong evidence of 
an adverse effect of pregnancy and an ameliorating effect of lactation. 
Importantly, the study was conducted in AA women, the population 
group at highest risk of ER- cancer. There have been three previous 
studies, mainly of European ancestry (EA) women, that also had a 
large number of ER- cases (25,27,38), but only one examined the 
joint effects of parity and lactation (27). That study, from the Breast 
Cancer Family Registry, included 920 ER-/PR- case patients, of 
which 131 were in AA women (27). Results were very similar to the 
present findings: High parity without lactation was positively associ-
ated with ER-/PR- breast cancer, whereas there was no association 
with high parity in women with a history of lactation (27). The EPIC 
study, with 998 ER- case patients, found no association of parity with 
ER- breast cancer (38). Of note, 81% of the participants had breast-
fed, as compared with only 43% of AMBER participants, and data 
were not presented on the relation of parity in the absence of lacta-
tion. In pooled data from the Breast Cancer Association Consortium 
(3895 ER- case patients), parity was not associated with risk of ER- 
cancer, and no data were available on lactation (25).
Each of the studies in our consortium has published on this 
topic previously, but the CBCS (8) and MEC (34) did not present 
results for AA women separately; parity was not associated with 
ER- cancer in the overall MEC data (34) but was associated with 
increased risk in the CBCS (8).
Analyses conducted within strata of ages at diagnosis and within 
strata of years since last birth indicate that the positive association of 
parity with ER- breast cancer is not limited to early-onset breast can-
cer and persists for many years after the pregnancy. The mechanisms 
behind this long-term effect may be different from the mechanisms 
operating for PABC, which occurs within 10 years of a pregnancy, a 
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Figure 2. Odds ratios for parity in relation to breast cancer according to years since last birth. Reference is nulliparous women.
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clinical disease irrespective of biologic subtype. Schedin et al. have 
hypothesized that an adverse effect of pregnancy may stem from 
immune system/inflammatory processes that occur during postpar-
tum involution (40). Involution involves an influx of immune cells, 
activation of fibroblasts, and extracellular matrix deposition, all 
hallmarks of a tumorigenic wound-healing environment (41). The 
mechanisms by which ER- breast cancer is selectively influenced by 
pregnancy and lactation are uncertain. Lactation may prevent disor-
dered involution and thus, possibly, the tissue inflammation associ-
ated with postpartum breast involution (42). Involution in women 
who have breastfed typically occurs gradually over a period of weeks 
or months as the mother moves from exclusive to partial breastfeed-
ing and then to less frequent feedings. Whether gradual weaning 
returns the lactating gland to its prepregnancy state in a more coor-
dinated and less tumorigenic process of apoptosis and remodeling 
remains to be determined. In addition, lactation may induce dif-
ferentiation of a population of cells susceptible to transformation, 
effectively depleting putative cancer-initiating cells (43). Here we 
provide evidence that ER- targets may be specifically reduced as 
a result of lactation. Further research is needed to understand the 
mechanisms by which ER- breast cancer could be selectively influ-
enced by pregnancy and lactation.
Parity was associated with a small reduction in risk of ER+ cancer 
if the first birth occurred before age 25 years, but not if the first birth 
was later. Breastfeeding was not associated with reduced risk of ER+ 
cancer. As reviewed by Althuis (4) and Ma (5), and consistent with pub-
lications since then (6,8,9,25,35,38), the vast majority of studies that 
have assessed parity in relation to risk of ER+ breast cancer have found 
either a weak inverse association with increasing number of births or 
no association. Findings regarding the relation of breastfeeding to risk 
of ER+ breast cancer have been less consistent, with some studies sug-
gesting an inverse association and others no association (44,45).
A limitation of the present study was a lack of data on HER2 for 
many case patients. Testing for HER2 expression did not become 
widespread until 2005, and additional testing by FISH for those 
with weak expression has been inconsistent and based on changing 
parameters. As a result, we were able to identify only 567 triple-
negative case patients out of all ER- case patients. We did not have 
a sufficient number of case patients with HER2 overexpression 
(ER-, PR-, HER2+) for separate analysis. We also did not have the 
additional markers needed for classification of luminal breast can-
cer or basal-like breast cancer.
Another limitation was the quality of the data on breastfeed-
ing. We did not have information on length of lactation for each 
birth, exclusive breastfeeding, or characterization of weaning. Thus 
we were unable to estimate the minimum duration required for a 
reduction in risk of ER- cancer.
Our findings suggest that parous women are at increased risk 
of ER- and triple-negative breast cancer, and that lactation may 
ameliorate the effects of pregnancy and childbirth. This may 
explain, in part, why AA women, who typically have more chil-
dren (13,14) but a lower prevalence of lactation than US white 
women (15,16), are disproportionately affected by ER- breast 
cancer. This profile, other factors being equal, would predict a 
higher incidence of ER- and triple-negative breast cancer, as has 
been observed in national data (1,2). A possible beneficial effect 
of lactation on future risk of ER- breast cancer is important 
information for the individual woman, who can take this into 
account when weighing the pros and cons of breastfeeding her 
baby. It is also critical information for the institutions whose poli-
cies determine whether lactation will be feasible for women who 
work outside the home.
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